# A Study of TAS-120 in Patients With Metastatic Breast Cancer

> **NCT04024436** · PHASE2 · TERMINATED · sponsor: **Taiho Oncology, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Metastatic Breast Cancer
- FGFR 1 High Amplification
- FGFR2 Amplification

## Interventions

- **DRUG:** Futibatinib
- **DRUG:** Futibatinib plus Fulvestrant

## Key facts

- **NCT ID:** NCT04024436
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-28
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-09-06
- **Target enrollment:** 64 (ACTUAL)
- **Why stopped:** The Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.
- **Last updated:** 2025-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04024436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04024436, "A Study of TAS-120 in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04024436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*